OKUR
OnKure Therapeutics, Inc.
$4.40
+5.01%
$177.7M
No data for this timeframe.
Vol
Market Cap$177.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders7 funds
Inst. Value$2.7M
Inst. Activity3 buys / 2 sells
Insider Activity0B / 2S
Insider Net $-$1.6K
SEC Reports3
Press Releases1
Recent Activity
Jun 4, 2026
Insider
Mathers Edward T sold 7,650 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Ratcliffe Liam sold 1,275 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Jansen Valerie Malyvanh sold 7,650 shares
Director @ $0.00 ($0.00)
May 12, 2026
earnings_calendar
OKUR Q1 2026 Earnings Scheduled — 2026-05-12
Apr 24, 2026
SEC
OnKure Therapeutics has filed an S-3 shelf registration to register 36.1 million shares of common stock for resale by se
S-3 — Impact 7/10
Apr 21, 2026
SEC
OnKure Therapeutics is holding a shareholder vote on director elections, with management soliciting votes. This filing i
DEFA14A — Impact 3/10
Mar 24, 2026
SEC
The CEO and CFO of OnKure Therapeutics sold small amounts of stock in the open market, totaling $1,609 in combined proce
CLUSTER — Impact 2/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
247,350 shares ($717.3K)
Price Targets
$20.20
+375.3% upside
Strong Buy
Current $4.25
Low $11.00
Median $17.00
High $30.00
5 analysts
$11.00
$30.00
Analyst Ratings
4Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.58 ▲ +10.6% | $-0.77 — $-0.41 | 49% YoY | 3 |
| Next Q | $-0.57 ▲ +9.4% | $-0.69 — $-0.41 | 47% YoY | 3 |
| Current FY | $-2.50 ▲ +5.7% | $-3.19 — $-1.92 | 43% YoY | 3 |
| Next FY | $-2.13 ▼ -3.6% | $-2.45 — $-1.86 | 15% YoY | 3 |
Latest Reports
BEARISH
S-3
7/10
OnKure Therapeutics has filed an S-3 shelf registration to register 36.1 million shares of common stock for resale by se
Apr 24, 2026
NEUTRAL
DEFA14A
3/10
OnKure Therapeutics is holding a shareholder vote on director elections, with management soliciting votes. This filing i
Apr 21, 2026
MIXED
Press
5/10
OnKure Therapeutics reported Q4 and full-year 2025 financial results, showing reduced R&D and G&A expenses leading to a
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $717.3K | ADD |
| MORGAN STANLEY | $72.4K | ADD |
| TWO SIGMA INVESTMENTS, LP | $32.8K | TRIM |
| WELLS FARGO & COMPANY/MN | $31.9K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Mathers Edward | A | $0.00 |
| Jun 4, 2026 | Ratcliffe Liam | A | $0.00 |
| Jun 4, 2026 | Jansen Valerie | A | $0.00 |
| Jun 4, 2026 | Phillips Andrew | A | $0.00 |
| Jun 4, 2026 | GREY MICHAEL | A | $0.00 |
7 institutional holders with $2.7M total value (921,766 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 626,593 | $1.8M | 68.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 247,350 | $717.3K | 26.8% | ADD +40.7% |
| 3 | MORGAN STANLEY | 24,962 | $72.4K | 2.7% | ADD +45.0% |
| 4 | TWO SIGMA INVESTMENTS, LP | 11,320 | $32.8K | 1.2% | TRIM -55.5% |
| 5 | WELLS FARGO & COMPANY/MN | 11,000 | $31.9K | 1.2% | DOUBLED +110.5% |
| 6 | FMR LLC | 400 | $1.2K | 0.0% | DOUBLED +700.0% |
| 7 | BANK OF AMERICA CORP /DE/ | 141 | $409.00 | 0.0% | NEAR_EXIT -84.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 175,750 | 247,350 | +40.7% | $717.3K | 2025-Q4 |
| MORGAN STANLEY | ADD | 17,214 | 24,962 | +45.0% | $72.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 25,435 | 11,320 | -55.5% | $32.8K | 2025-Q4 |
| FMR LLC | DOUBLED | 50 | 400 | +700.0% | $1.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 896 | 141 | -84.3% | $409.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 122,636 | 175,750 | +43.3% | $483.3K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 41,863 | 122,636 | +192.9% | $293.1K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 1,878 | 16,701 | +789.3% | $39.9K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 3,620 | 7,620 | +110.5% | $18.2K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 221 | 848 | +283.7% | $2.0K | 2025-Q2 |
| UBS Group AG | TRIM | 280 | 181 | -35.4% | $433.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 27,148 | — | $116.7K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,620 | 3,620 | +123.5% | $15.6K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 932 | 1,878 | +101.5% | $8.1K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 2,213 | 280 | -87.3% | $1.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 1,074,314 | — | $8.8M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 47,450 | — | $408.1K | 2024-Q4 |
| UBS Group AG | NEW | — | 2,213 | — | $19.0K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | NEW | — | 1,620 | — | $13.9K | 2024-Q4 |
10 unique insiders with 2 transactions. Net insider value: -$1.6K ($0.00 bought, $1.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Mathers Edward T | Director | A | 7,650 | $0.00 | $0.00 |
| Jun 4, 2026 | Ratcliffe Liam | Director | A | 1,275 | $0.00 | $0.00 |
| Jun 4, 2026 | Jansen Valerie Malyvanh | Director | A | 7,650 | $0.00 | $0.00 |
| Jun 4, 2026 | Phillips Andrew John | Director | A | 7,650 | $0.00 | $0.00 |
| Jun 4, 2026 | GREY MICHAEL G | Director | A | 7,650 | $0.00 | $0.00 |
| Jun 4, 2026 | Carruthers R Michael | Director | A | 7,650 | $0.00 | $0.00 |
| Apr 1, 2026 | Hartley Dylan | Chief Scientific Officer | A | 110,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Leverone Jason A. | Chief Financial Officer | A | 110,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Saccomano Nicholas A | President and CEO | A | 330,000 | $0.00 | $0.00 |
| Apr 1, 2026 | Agresta Samuel | Chief Medical Officer | A | 110,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Ratcliffe Liam | Director | A | 15,300 | $0.00 | $0.00 |
| Mar 23, 2026 | Leverone Jason A. | Chief Financial Officer | SELL | 301 | $4.16 | $1.3K |
| Mar 23, 2026 | Saccomano Nicholas A | President and CEO | SELL | 86 | $4.16 | $357.46 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
BEARISH
S-3
7/10
OnKure Therapeutics has filed an S-3 shelf registration to register 36.1 million shares of common st
Apr 24, 2026
NEUTRAL
DEFA14A
3/10
OnKure Therapeutics is holding a shareholder vote on director elections, with management soliciting
Apr 21, 2026
NEUTRAL
CLUSTER
2/10
The CEO and CFO of OnKure Therapeutics sold small amounts of stock in the open market, totaling $1,6
Mar 24, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.20 mean target
+375.3% upside
Strong Buy (3.00)
$11.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $4.25 |
| Target Low | $11.00 |
| Target Mean | $20.20 |
| Target Median | $17.00 |
| Target High | $30.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.58 | $-0.77 | $-0.41 | 48.8% | +10.6% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.57 | $-0.69 | $-0.41 | 47.4% | +9.4% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-2.50 | $-3.19 | $-1.92 | 43.1% | +5.7% | — | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-2.13 | $-2.45 | $-1.86 | 14.9% | -3.6% | 3↑ 0↓ | $0.0B | 77.8% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.583 | |
| 7d ago | $-0.652 | +0.069 |
| 30d ago | $-0.652 | +0.069 |
| 60d ago | $-1.030 | +0.447 |
| 90d ago | $-1.180 | +0.597 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
OKUR Q1 2026 Earnings Scheduled — 2026-05-12
May 5, 2026
earnings
OnKure Therapeutics Reports First Quarter 2026 Financial Results
<p align="center"><em>-- Announced nomination of OKI-355, a next-generation PI3Kα </em><em>pan-mutant selective inhibitor candidate, in vascular anoma
May 4, 2026
earnings_calendar
OKUR Q1 2026 Earnings Scheduled — 2026-05-04
Apr 24, 2026
short_interest
FTD: OKUR — 182,052 shares ($0.9M) failed to deliver
Settlement: 20260424, Price: $4.90, FTD Value: $892,054.8, ONKURE THERAPEUTICS, INC. CLAS
Mar 16, 2026
earnings_calendar
OKUR Q4 2025 Earnings After Market Close — 2026-03-16
Mar 12, 2026
earnings
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="center"><em>-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026</em><em>; <br>continued enrollment in breast
Mar 9, 2026
earnings_calendar
OKUR Q4 2025 Earnings After Market Close — 2026-03-09